Also from this source

You just read:

Phosplatin Therapeutics Announces First Cohort Enrolled in Phase I / II Trial of PT-112 in Relapsed / Refractory Multiple Myeloma, and Receipt of FDA Orphan Drug Designation

News provided by

Phosplatin Therapeutics

Feb 07, 2018, 10:15 EST